Company Overview
Burning Rock Biotech Limited operates within the healthcare sector, specifically focusing on the diagnostics and research industry where it develops and sells cancer therapy selection tests across the People's Republic of China and the United States. The company structures its operations into three distinct segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services, offering next-generation solutions for these therapeutic areas. The firm maintains a market capitalization of $220.72M and generates annual revenue of $539.57M, while the total employee count is currently listed as N/A. These financial figures indicate that the company holds a mid-to-large scale position in its niche, evidenced by a market cap that is substantial relative to its annual revenue stream, suggesting a significant market presence despite the lack of publicly disclosed headcount data to gauge operational breadth directly.
Financial Health
The company reports a trailing twelve-month revenue of $539.57M, yet this generates a net income of $-55,346,000 and an EBITDA of $-3,458,000, revealing a cost structure where operating expenses and research expenditures significantly outpace current profitability. The free cash flow stands at $-41,697,876, indicating that the company is currently burning cash, which limits immediate financial flexibility and suggests capital is being consumed to fund ongoing development and expansion rather than returned to shareholders. Margin analysis shows a gross margin of 74.7%, reflecting high pricing power or low cost of goods sold in the initial production phase, contrasted sharply by an operating margin of -9.5% and a profit margin of -10.3%, which highlights significant overhead costs and the challenges of achieving overall profitability at this stage. The balance sheet displays $478.39M in cash against $43.12M in debt, resulting in a debt-to-equity ratio of 8.06, which suggests a highly leveraged capital structure relative to equity, although the substantial cash pile provides a significant buffer against short-term obligations. Liquidity is robust as indicated by a current ratio of 2.99, meaning the company possesses nearly three times the current assets necessary to cover its short-term liabilities without immediate distress. Return metrics further illustrate financial performance with a return on equity of -9.9% and a return on assets of -4.0%, revealing that management effectiveness in generating profit from the capital base and total assets remains negative, likely due to the heavy investment required in the biotechnology research and development lifecycle.
Valuation Assessment
Valuation multiples reflect the company's lack of current earnings, with a trailing P/E ratio listed as N/A and a forward P/E of -35.34, implying that the market is not pricing the stock based on historical profitability but rather on future expectations of earnings recovery or growth. The price-to-book ratio is 2.77, indicating that the market values the company at a premium of 177% over its tangible book value, a common characteristic for biotech firms with valuable intellectual property that is not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 0.41 and an EV/EBITDA of -495.23, suggesting that investors are willing to pay a fraction of sales revenue for the company, despite the negative earnings multiple, which often points to high-growth potential or significant upcoming clinical milestones. Price action shows a 52-week high of $41.72 and a 52-week low of $2.18; given the wide range, the current valuation context depends on the specific share price, but the spread indicates high volatility where the stock can trade anywhere within a range spanning nearly 19 times its recent low. The beta value is 1.45, which signifies that the stock's price volatility is 45% higher than the broader market, meaning it is expected to move more aggressively than the S&P 500 during periods of market instability.
Growth & Income
Revenue growth year-over-year is recorded at 0.2%, while earnings growth is N/A, indicating that the company is currently stable in terms of top-line expansion but has not yet achieved a trajectory of earnings growth that outpaces revenue due to its negative net income position. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm reinvests all available cash flow back into operations, research, and development rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology companies in the development phase, where capital is prioritized for bringing new therapies to market rather than providing current income to investors. The overall growth and income profile is characterized by a focus on revenue stabilization and operational scaling, with income generation expected to improve only after significant cost reductions or successful commercialization of its cancer therapy selection tests.